A Phase 2 interventional study of Partially covered SEMS and Fully covered SEMS in Esophageal Cancer, Cancer of Gastro Esophageal Junction and Palliative Treatment, sponsored by Karolinska University Hospital. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-05.
Sponsored by Karolinska University Hospital · Phase 2, Interventional, and Treatment
Self expandable stent (SEMS) constitutes the main palliative treatment in advanced esophageal cancer. The palliative effect of SEMS is immediate when it comes to relief of dysphagia. The duration of this effect is however questionable. The design of SEMS can be of importance since the device can dislodge and as a consequence of that dysphagia recur. The hypothesis has therefore been formulated that a partially covered SEMS is associated with less tendency to dislocate as compared to those SEMS, recently developed, which are covered through their entire length.
Karolinska University Hospital is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Boston Scientific Ultraflex SEMS
Device: Partially covered SEMS
Boston Scientific Wallflex Esophageal SEMS.
Device: Fully covered SEMS
SEMS dislocation in cm during first thirty days after stent insertion.
Time frame: Thirty days from stent deployment.
Health Related Quality of Life (HRQOL)
Time frame: Within three months of SEMS deployment.
Need for reintervention
Time frame: Within three months after SEMS
Grade of dysphagia within three months of SEMS.
Time frame: Three months after insertion.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karolinska University Hospital